It hasn't been an easy start to May for CoreWeave (NASDAQ: CRWV) . The artificial intelligence (AI) infrastructure provider tumbled more than 10% this month as of May 12, raising the question of whether this sell-off is justified or if investors should buy the dip. It's important to first understand what rattled the stock. Ultimately, CoreWeave posted solid numbers for this quarter, but its second...
It hasn't been an easy start to May for CoreWeave (NASDAQ: CRWV) . The artificial intelligence (AI) infrastructure provider tumbled more than 10% this month as of May 12, raising the question of whether this sell-off is justified or if investors should buy the dip. It's important to first understand what rattled the stock. Ultimately, CoreWeave posted solid numbers for this quarter, but its second-quarter guidance fell short of Wall Street's consensus expectations. This, combined with the fact that operating costs more than doubled to $2.2 billion from the same quarter last year, has investors wondering whether the high spending will pay off as growth slows. CoreWeave anticipates higher capital expenditures over the next quarter as well, which is again shaking investor confidence. CoreWeave's aggressive spending and debt load are putting pressure on the balance sheet and margins. Losses this quarter were higher than at this same time last year, according to the company's earnings report. Continue reading
Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q1 2026 Management View "Since submitting GraftAssureDx to the FDA in late March, we've had a high degree of engagement from them and expect that, that will continue as we move through the review process," said (President, CEO & Director Joshua Riggs), adding, "We expect our first U.S. orders for GraftAssure later this year." "We've comm...
Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q1 2026 Management View "Since submitting GraftAssureDx to the FDA in late March, we've had a high degree of engagement from them and expect that, that will continue as we move through the review process," said (President, CEO & Director Joshua Riggs), adding, "We expect our first U.S. orders for GraftAssure later this year." "We've committed to delivering software-like margins with GraftAssure," said (President, CEO & Director Riggs), and described commercial preparation: "Over the past several months, we surveyed over 200 likely U.S. purchasers working through multiple pricing and purchasing scenarios to guide our pricing strategy." "Outside of the U.S., we've seen some encouraging market access progress" for GraftAssureIQ, said (President, CEO & Director Riggs), citing early non-U.S. activity: "a Swiss transplant hospital purchased a small number of kits, and we are expecting our first orders out of Southeast Asia" and noting, "At least one of these centers was able to establish coverage and reimbursement for the test in its market." "So far, 34 U.S. transplant centers have expressed interest in being part of our registry. This is up from 28 centers just 6 weeks ago" and "represents remarkable progress toward our 50-center goal," said (President, CEO & Director Riggs), also highlighting a monetization element of the registry: "Medicare reimburses GraftAssureCore at a rate of $2,753 per result." "Our first quarter results are in line with what we told you they would be" and "our financial projections remain consistent with the update that we provided in late March," said (Chief Financial Officer Andrea James), adding, "This management team remains highly thoughtful about extending our cash runway and focusing our commercialization investments towards the areas that we believe will drive optimal ROI for the company." Outlook "Our Q2 2026 revenue projection is for about $0.25 million, comprised mostly of l...
ismagilov/iStock via Getty Images Portfolio Review Cautious optimism gave way to tumultuous headwinds. Equities began the quarter with a relatively constructive backdrop. However, fears of artificial intelligence disruption led to heavy selling in software and technology-related stocks and weighed on broader sentiment. The war in Iran further destabilized markets as oil prices spiked. Small-cap st...
ismagilov/iStock via Getty Images Portfolio Review Cautious optimism gave way to tumultuous headwinds. Equities began the quarter with a relatively constructive backdrop. However, fears of artificial intelligence disruption led to heavy selling in software and technology-related stocks and weighed on broader sentiment. The war in Iran further destabilized markets as oil prices spiked. Small-cap stocks outperformed large caps, and value fared better than growth. The Fed held interest rates steady. The Federal Reserve (Fed) kept its benchmark rate unchanged in the first quarter amid surging oil prices and uncertainty surrounding the war in Iran. Annual headline inflation held steady at 2.4% in January and February, while the annual core personal consumption expenditure price index climbed to 3.1% in January, above the Fed's 2% target rate. The U. S. unemployment rate rose to 4.4% in February. Financials holdings weighed on relative performance. Stock selection among banks was the primary source of weakness in the sector, as Coastal Financial ( CCB ) underperformed. Capital markets positions also detracted. Consumer discretionary positioning detracted. Underweight exposure to diversified consumer services relative to the benchmark was a drag, while an overweight in specialty retail also presented headwinds, including our position in The RealReal ( REAL ). Information technology stock selection was a source of strength. Semiconductors industry holdings, including Silicon Laboratories ( SLAB ) and MKS ( MKSI ), were key drivers of outperformance in the sector. Electronic equipment manufacturer Plexus ( PLXS ) also contributed notably. Key Contributors Silicon Laboratories. The company has benefited from accelerating demand for its system-on-chip solutions due to secular adoption of the Internet of Things in commercial and industrial applications. Its strong structural characteristics caught the eye of Texas Instruments ( TXN ), which announced it was acquiring Silicon La...
America's Fanatical Left Wing Mayors Are A Malignant Threat This week the Democrat mayor of Arcadia, CA pled guilty to charges of acting as an illegal agent of the People’s Republic of China. Prosecutors alleged that from 2020–2022 (pre-mayor but continuing into her time in office), she and an associate operated a website promoting pro-China propaganda at the direction of PRC officials, without re...
America's Fanatical Left Wing Mayors Are A Malignant Threat This week the Democrat mayor of Arcadia, CA pled guilty to charges of acting as an illegal agent of the People’s Republic of China. Prosecutors alleged that from 2020–2022 (pre-mayor but continuing into her time in office), she and an associate operated a website promoting pro-China propaganda at the direction of PRC officials, without registering as a foreign agent. She faces at up to 10 years in prison for the crime, and it raises questions about how many more US mayors are on the payroll of foreign governments. But this scandal, like most scandals surrounding Democrats, will probably be erased from public discussion and forgotten within days. It's a tale that keeps repeating over the last decade and the lack of scrutiny (or pattern recognition) is leading to devastating consequences for the US as a whole. The common reaction among many conservatives when they come across such news is to dismiss it as predictable. "The idiots living in that city got exactly what they voted for..." is the often heard retort. The implication being that it's "not our problem" and that leftists should be allowed to rot in the hellholes they created for themselves. But the truth is, it is a problem, for the entire country. It's difficult to determine when it became fashionable for conservatives and centrists to abandon the fight for America's cities, but the consequences are spreading like a cancer into the political sphere. Leftists view these cities as victories. They see them as "territories, or "home bases" where they can launch assaults on various targets without fear of serious prosecution. Allowing this takeover to continue should be treated as embarrassing by anyone with a modicum of moral clarity. Failing metros also represent symbols of embarrassment on the global stage. When people around the world see the fentanyl zombie hordes of San Francisco or Philadelphia, that image sticks in their minds as a meme for the US....
Lima The U.S. House of Representatives passed legislation Wednesday to allow year-round sales of higher-ethanol E15 gasoline across the U.S., in a victory for corn farmers after more than a decade of failed attempts to expand the market for E15. The legislation still needs approval in the Senate, where its prospects are uncertain, and then support from the president. E15—gasoline made with 15% cor...
Lima The U.S. House of Representatives passed legislation Wednesday to allow year-round sales of higher-ethanol E15 gasoline across the U.S., in a victory for corn farmers after more than a decade of failed attempts to expand the market for E15. The legislation still needs approval in the Senate, where its prospects are uncertain, and then support from the president. E15—gasoline made with 15% corn-based ethanol—could provide a meaningful boost to farm profits at a time when growers are dealing with record crops and rising costs of inputs such as fertilizer. " At a time of extreme market volatility and higher costs, this bill provides badly needed certainty for fuel retailers, oil refiners, ethanol producers, and consumers alike," Renewable Fuels Association President Geoff Cooper said. Potentially relevant stocks include Archer Daniels Midland ( ADM ), Bunge ( BG ), Green Plains ( GPRE ), Gevo ( GEVO ), Clean Energy Fuels ( CLNE ), REX American Resources ( REX ), Darling Ingredients ( DAR ), FutureFuel ( FF ), Valero Energy ( VLO ), Marathon Petroleum ( MPC ), Phillips 66 ( PSX ), HF Sinclair ( DINO ), PBF Energy ( PBF ), Delek US ( DK ). ETFs: ( CORN ), ( SOYB ), ( WEAT ), ( DBA ), ( MOO ) More on Archer Daniels Midland, Valero Energy, and Green Plains Archer Daniels Midland: Why My Cautious Outlook In 2021 Was Correct Valero Energy: A Repeat Of The Mega-Cycle From 2022 Green Plains: Time To Harvest The Greenbacks
In this article TM TCS-IN GOOGL USB Follow your favorite stocks CREATE FREE ACCOUNT Hello, this is Priyanka Salve, writing to you from Singapore. Welcome to the latest edition of " Inside India " — your one-stop destination for stories and developments from the world's fastest-growing large economy. For more than two decades, consecutive U.S. administrations have seen India as a counterbalance to ...
In this article TM TCS-IN GOOGL USB Follow your favorite stocks CREATE FREE ACCOUNT Hello, this is Priyanka Salve, writing to you from Singapore. Welcome to the latest edition of " Inside India " — your one-stop destination for stories and developments from the world's fastest-growing large economy. For more than two decades, consecutive U.S. administrations have seen India as a counterbalance to China's growing influence in the Indo-Pacific. But the current U.S administration's stances seem to favour Beijing while punishing India. This week, I unpack how the U.S.-China summit could impact New Delhi's equation with Washington. Read on! Any thoughts on today's newsletter? Share them with the team. The big story U.S. President Donald Trump and Chinese President Xi Jinping shake hands as they depart following a bilateral meeting at Gimhae Air Base on October 30, 2025 in Busan, South Korea. Andrew Harnik | Getty Images India, whose significance to the U.S. foreign policy has been shaped by frictions between Washington and Beijing, will be keeping a close eye on the meeting between President Donald Trump and his Chinese counterpart, Xi Jinping. When the summit between the world's top two economies begins later in the day, India will be hoping that Trump's softening stance toward China does not lead to a bargain that diminishes New Delhi's role in the Indo-Pacific, experts said. If Trump prioritizes a bilateral grand bargain with Beijing, India will have "reasonable concerns that the United States will treat China as the central negotiating partner in Asia rather than as the central strategic challenge," Ronak D. Desai, visiting fellow at the Hoover Institution, Stanford University, told CNBC. Therefore, "India will need to make its strategic value harder to overlook," Desai said, adding this would mean the U.S.-India relationship must lead to more tangible outcomes in sectors like defense, maritime security, critical minerals, energy, and manufacturing. Trump and Xi last...